{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:34:45Z","timestamp":1768340085821,"version":"3.49.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3,15]]},"DOI":"10.2146\/ajhp140221","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T00:36:32Z","timestamp":1425429392000},"page":"439-447","source":"Crossref","is-referenced-by-count":19,"title":["Bosutinib for the treatment of chronic myeloid leukemia"],"prefix":"10.1093","volume":"72","author":[{"given":"Vi","family":"Doan","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary","family":"Prescott","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041008223991500_b1-0720439","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic myelogenous leukemia, version 1 (2014). www.nccn.org (accessed 2013 Dec 27)."},{"key":"key\n\t\t\t\t2019041008223991500_b2-0720439","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008223991500_b3-0720439","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1345\/aph.1P784","article-title":"Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners","volume":"45","author":"Wong","year":"2011","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041008223991500_b4-0720439","first-page":"99","article-title":"Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia","volume":"6","author":"Amsberg","year":"2013","journal-title":"Onco Targets Ther"},{"key":"key\n\t\t\t\t2019041008223991500_b5-0720439","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key\n\t\t\t\t2019041008223991500_b6-0720439","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b7-0720439","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008223991500_b8-0720439","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs sti571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (cml-cp) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b9-0720439","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008223991500_b10-0720439","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b11-0720439","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008223991500_b12-0720439","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly amn107), a highly selective bcr-abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b13-0720439","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008223991500_b14-0720439","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","article-title":"ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMENA working party on chronic myeloid leukemia","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041008223991500_b15-0720439","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b16-0720439","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b17-0720439","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","article-title":"Evolution of therapies for chronic myelogenous leukemia","volume":"17","author":"Santos","year":"2011","journal-title":"Cancer J"},{"key":"key\n\t\t\t\t2019041008223991500_b18-0720439","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008223991500_b19-0720439","volume-title":"Bosulif (bosutinib) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041008223991500_b20-0720439","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1586\/era.12.84","article-title":"Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia","volume":"12","author":"Keller","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"key\n\t\t\t\t2019041008223991500_b21-0720439","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041008223991500_b22-0720439","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b23-0720439","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041008223991500_b24-0720439","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019041008223991500_b25-0720439","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","article-title":"A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects","volume":"69","author":"Abbas","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2019041008223991500_b26-0720439","first-page":"115","article-title":"Bosutinib in the management of chronic myelogenous leukemia","volume":"7","author":"Amsberg","year":"2013","journal-title":"Biologics"},{"key":"key\n\t\t\t\t2019041008223991500_b27-0720439","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b28-0720439","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V122.21.2723.2723","article-title":"Bosutinib as therapy for chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib: 48-month update","volume":"122","author":"Brummendorf","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b29-0720439","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1182\/blood.V122.21.4025.4025","article-title":"Bosutinib as therapy for chronic phase chronic myeloid leukemia following failure with imatinib plus dasatinib and\/or nilotinib: 36-month update","volume":"122","author":"Cortes","year":"2013","journal-title":"Blood"},{"issue":"15, suppl","key":"key\n\t\t\t\t2019041008223991500_b30-0720439","article-title":"Safety and efficacy of bosutinib in patients with AP and BP CML and Ph+ all following resistance\/intolerance to imatinib and other TKIs: update from study SKI-200","volume":"28","author":"Gambacorti-Passerini","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"key\n\t\t\t\t2019041008223991500_b31-0720439","article-title":"BELA trial update: bosutinib (bos) versus imatinib (im) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (cp cml) after 30 months of follow-up","volume":"30","author":"Gambacorti-Passerini","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041008223991500_b32-0720439","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2010-04-279752","article-title":"New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases","volume":"116","author":"Toffalini","year":"2010","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b33-0720439","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b34-0720439","volume-title":"Red Book Online [Internet database]"},{"key":"key\n\t\t\t\t2019041008223991500_b35-0720439","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041008223991500_b36-0720439","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.V122.21.1484.1484","article-title":"Assessment of early cytogenetic response by 3 months versus >3\u20136 months or no response by 6 months as a predictor of long-term clinical outcomes in a phase 1\/2 study of bosutinib in chronic phase CML","volume":"122","author":"Cortes","year":"2013","journal-title":"Blood"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/72\/6\/439\/28319244\/ajhp0439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T13:48:46Z","timestamp":1598795326000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/72\/6\/439\/5111664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,15]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,3,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140221","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,3,15]]},"published":{"date-parts":[[2015,3,15]]}}}